Piramal Pharma Limited (PPLPHARMA) Price & Analysis

Compare

11 Followers

PPLPHARMA Stock Chart & Stats

₹192.65

-₹4.80(-1.92%)

At close: Jan 08 4:00 PM EST

₹192.65

-₹4.80(-1.92%)

Day’s Range― - ―

52-Week Range₹148.30 - ₹241.00

Previous CloseN/A

Volume1.66M

Average Volume (3M)264.14K

Market Cap

₹220.52B

Enterprise Value₹262.91B

Total Cash (Recent Filing)₹4.08B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)―

Beta0.80

Next Earnings

May 27, 2026

EPS Estimate

0.84

Next Dividend Ex-DateN/A

Dividend Yield0.08%

Share Statistics

EPS (TTM)-0.70

Shares Outstanding1,329,248,200

10 Day Avg. Volume501,791

30 Day Avg. Volume264,138

Financial Highlights & Ratios

PEG Ratio0.84

Price to Book (P/B)3.72

Price to Sales (P/S)3.30

P/FCF Ratio132.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Diversified Business ModelPiramal's dual model—CDMO services plus specialty pharma—creates durable revenue streams: long-term supply contracts and milestone fees in CDMO plus branded product sales. This diversification reduces single-market risk and supports steadier cash flow over cycles.

Manageable Leverage And Equity BaseA 0.60 debt/equity and healthy equity ratio indicate balanced capitalization. Manageable leverage lowers refinancing risk, preserves flexibility for capex or bolt-on investments, and makes the balance sheet more resilient to industry cycles or project timing variability.

High Gross Margin And Improving Operating EfficiencyA ~64.7% gross margin signals strong manufacturing economics or pricing power in APIs and formulation. The marked EBIT improvement shows operational leverage and cost control, supporting sustainable improvement in profitability as revenue scales and higher‑value projects win.

Bears Say

Volatile Free Cash FlowSignificant swings in free cash flow suggest capex timing or working capital variability, which can constrain reinvestment, deleverage efforts, or shareholder returns. Persistent FCF volatility reduces predictability of internally funded growth and strategic flexibility.

Inconsistent Net Profit MarginsErratic net margins imply earnings volatility driven by mix, one-offs, or cost variability. This undermines earnings predictability, complicates long-term planning and guidance, and may necessitate external financing during downturns or before new projects reach steady state.

Moderately Low EBITDA MarginA relatively modest EBITDA margin limits the internal cushion to absorb input cost inflation and fund growth. Lower operational cash conversion makes the company more reliant on execution improvements or external capital to expand capacity or invest in higher‑value technologies.

Piramal Pharma Limited News

Piramal Critical Care and Blue-Zone Partner to Recycle Waste Anaesthetic Gases

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has issued an announcement. Piramal Critical Care, Inc. and Canada-based Blue-Zone Technologies...

12d ago

Piramal Pharma to Acquire Kenalog Injectable Portfolio from Bristol-Myers Squibb

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has provided an update. Piramal Pharma’s step-down wholly owned subsidiary, Piramal Critical...

20d ago

Piramal Pharma Strengthens Senior Management, Appoints Interim Company Secretary

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has issued an update. Piramal Pharma Limited has expanded its senior management...

20d ago

Piramal Pharma Posts Higher Profit Despite Softer Revenue in Q3 FY26

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has shared an update. Piramal Pharma Limited’s board has approved the unaudited...

20d ago

Piramal Pharma Posts Muted Q3 FY26 Results but Signals Early Recovery and Continued Expansion

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) has provided an update. Piramal Pharma Limited reported a 3% year-on-year decline...

20d ago

Piramal Pharma Reshuffles Senior Management and Appoints Interim Company Secretary

An update from Piramal Pharma Limited ( ($IN:PPLPHARMA) ) is now available. Piramal Pharma Limited’s board has expanded...

20d ago

Piramal Pharma Posts Q3 Loss as CDMO Weakness Weighs, Signals Early Demand Recovery

The latest update is out from Piramal Pharma Limited ( ($IN:PPLPHARMA) ). Piramal Pharma reported a weak performance...

20d ago

Piramal Pharma Revamps Senior Management, Appoints New Compliance Chief

Piramal Pharma Limited ( ($IN:PPLPHARMA) ) just unveiled an update. Piramal Pharma Limited has overhauled its senior management...

20d ago

Piramal Pharma Revamps Senior Management and Key Compliance Role

The latest announcement is out from Piramal Pharma Limited ( ($IN:PPLPHARMA) ). Piramal Pharma Limited has announced a...

20d ago

Piramal Pharma Shareholders Approve Appointment of Independent Director via Postal Ballot

The latest announcement is out from Piramal Pharma Limited ( ($IN:PPLPHARMA) ). Piramal Pharma Limited has announced that...

1M ago

PPLPHARMA FAQ

What was Piramal Pharma Limited’s price range in the past 12 months?

Piramal Pharma Limited lowest stock price was ₹148.30 and its highest was ₹241.00 in the past 12 months.

What is Piramal Pharma Limited’s market cap?

Piramal Pharma Limited’s market cap is ₹220.52B.

When is Piramal Pharma Limited’s upcoming earnings report date?

Piramal Pharma Limited’s upcoming earnings report date is May 27, 2026 which is in 98 days.

How were Piramal Pharma Limited’s earnings last quarter?

Piramal Pharma Limited released its earnings results on Jan 28, 2026. The company reported -₹0.7 earnings per share for the quarter, missing the consensus estimate of -₹0.245 by -₹0.455.

Is Piramal Pharma Limited overvalued?

According to Wall Street analysts Piramal Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Piramal Pharma Limited pay dividends?

Piramal Pharma Limited pays a Notavailable dividend of ₹0.14 which represents an annual dividend yield of 0.08%. See more information on Piramal Pharma Limited dividends here

What is Piramal Pharma Limited’s EPS estimate?

Piramal Pharma Limited’s EPS estimate is 0.84.

How many shares outstanding does Piramal Pharma Limited have?

Piramal Pharma Limited has 1,329,248,200 shares outstanding.

What happened to Piramal Pharma Limited’s price movement after its last earnings report?

Piramal Pharma Limited reported an EPS of -₹0.7 in its last earnings report, missing expectations of -₹0.245. Following the earnings report the stock price went up 1.015%.

Which hedge fund is a major shareholder of Piramal Pharma Limited?

Currently, no hedge funds are holding shares in IN:PPLPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Piramal Pharma Limited

Piramal Pharma Limited (PPLPHARMA) is a leading global pharmaceutical company based in India, operating under the Piramal Group. The company focuses on developing and manufacturing a wide range of pharmaceutical products, including branded and generic formulations, active pharmaceutical ingredients (APIs), and contract development and manufacturing services (CDMO). PPLPHARMA is committed to providing innovative healthcare solutions across various therapeutic areas such as oncology, cardiovascular, and central nervous system disorders, leveraging its extensive research and development capabilities.